FYI From Human Genome Sciences, Inc. (HGSI): GlaxoSmithKline (GSK) Announces Positive Data from Harmony 8 Phase 3 Trial and Completion of Clinical Registration Package for Albiglutide in Type 2 Diabetes
7/11/2012 10:09:28 AM
ROCKVILLE, Md.--(BUSINESS WIRE)--Attached is a press release issued earlier today by GlaxoSmithKline, announcing that data have been received from the Phase 3 Harmony 8 study and from the event-driven meta-analysis for assessment of cardiovascular safety conducted across the albiglutide clinical program in type 2 diabetes. These data are the final elements required to complete the clinical registration package.
comments powered by